Outcome in breast molecular subtypes according to nodal status and surgical procedures

American Journal of Surgery

Volumn 205, Issue 6, 2013, Pages 662-667

  Mazouni, Chafika ^a   Rimareix, Françoise ^a   Mathieu, Marie Christine ^a   Uzan, Catherine ^a   Bourgier, Céline ^a   André, Fabrice ^a   Delaloge, Suzette ^a   Garbay, Jean Rémi ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Breast cancer; Luminal B; Molecular subtype; Triple negative

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; ARTICLE; BREAST CANCER; BREAST CANCER MOLECULAR SUBTYPE; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURGERY; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; PARTIAL MASTECTOMY; PRIMARY TUMOR; PRIORITY JOURNAL; SENTINEL LYMPH NODE BIOPSY;

ADULT; BREAST NEOPLASMS; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MASTECTOMY; MASTECTOMY, SEGMENTAL; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; SENTINEL LYMPH NODE BIOPSY;

EID: 84877810317     PISSN: 00029610     EISSN: 18791883     Source Type: Journal    
DOI: 10.1016/j.amjsurg.2012.06.006     Document Type: Article

References (30)

1. C.M. Perou, T. Sorlie, and M.B. Eisen Molecular portraits of human breast tumours Nature 406 2000 747 752
2. T. Sorlie, C.M. Perou, and R. Tibshirani Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci U S A 98 2001 10869 10874
3. R. Rouzier, C.M. Perou, and W.F. Symmans Breast cancer molecular subtypes respond differently to preoperative chemotherapy Clin Cancer Res 11 2005 5678 5685
4. L. Harris, H. Fritsche, R. Mennel American Society of Clinical Oncology American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer J Clin Oncol 25 2007 5287 5312
5. C.M. Sturgeon, M.J. Duffy, U.H. Stenman National Academy of Clinical Biochemistry National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumour markers in testicular, prostate, colorectal, breast, and ovarian cancers Clin Chem 54 2008 e11 e79
6. N.D. Arvold, A.G. Taghian, and A. Niemierko Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy J Clin Oncol 29 2011 3885 3891
7. B.G. Haffty, Q. Yang, and M. Reiss Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer J Clin Oncol 24 2006 5652 5657
8. J. O'Shaughnessy, C. Osborne, and J.E. Pippen Iniparib plus chemotherapy in metastatic triple-negative breast cancer N Engl J Med 364 2011 205 214
9. L.A. Carey, H.S. Rugo, and P.K. Marcom TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer J Clin Oncol 30 2012 2615 2623
10. H.J. Burstein, A.D. Elias, and H.S. Rugo Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane J Clin Oncol 26 2008 1810 1816
11. S. Loi, E. de Azambuja, and L. Pugliano HER2-overexpressing breast cancer: time for the cure with less chemotherapy? Curr Opin Oncol 23 2011 547 558
12. J.S. Ross Update on HER2 testing for breast and upper gastrointestinal tract cancers Biomark Med 5 2011 307 318
13. R. Callahan, and S. Hurvitz Human epidermal growth factor receptor-2-positive breast cancer: current management of early, advanced, and recurrent disease Curr Opin Obstet Gynecol 23 2011 37 43
14. V. Abramson, and C.L. Arteaga New strategies in HER2-overexpressing breast cancer: many combinations of targeted drugs available Clin Cancer Res 17 2011 952 958
15. J.A. Van der Hage, J.S. Mieog, and C.J. van de Velde Impact of established prognostic factors and molecular subtype in very young breast cancer patients: pooled analysis of four EORTC randomized controlled trials Breast Cancer Res 13 2011 R68
16. F. Reyal, R. Rouzier, and B. Depont-Hazelzet The molecular subtype classification is a determinant of sentinel node positivity in early breast carcinoma PLoS One 6 2011 e20297
17. G. Contesso, H. Mouriesse, and S. Friedman The importance of histologic grade in long-term prognosis of breast cancer: a study of 1,010 patients, uniformly treated at the Institut Gustave-Roussy J Clin Oncol 5 1987 1378 1386
18. A. Goldhirsch, J.N. Ingle, and R.D. Gelber Panel members. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009 Ann Oncol 20 2009 1319 1329
19. R Development Core Team (2010). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. Available at: http://www.R-project.org/. Accessed January, 2013.
20. S.J. Crabb, M.C.U. Cheang, and S. Leung Basal breast cancer molecular subtype predicts for lower incidence of axillary lymph node metastases in primary breast cancer Clin Breast Cancer 8 2008 249 256
21. B. Van Calster, I. Vanden Bempt, and M. Drijkoningen Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive Breast Cancer Res Treat 113 2009 181 187
22. O. Brouckaert, S. Pintens, and V. Van Belle Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors Breast Cancer Res Treat 115 2009 349 358
23. L.A. Carey, C.M. Perou, and C.A. Livasy Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study JAMA 295 2006 2492 2502
24. J.M. Bartlett, I.O. Ellis, and M. Dowsett Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy J Clin Oncol 25 2007 4423 4430
25. D.J. Slamon, G.M. Clark, and S.G. Wong Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 1987 177 182
26. K.M. O'Brien, S.R. Cole, and C.K. Tse Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study Clin Cancer Res 16 2010 6100 6110
27. G. Cancello, P. Maisonneuve, and N. Rotmensz Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer Ann Oncol 21 2010 1974 1981
28. Y.H. Park, S.J. Lee, and E.Y. Cho Clinical relevance of TNM staging system according to breast cancer subtypes Ann Oncol 22 2011 1554 1560
29. A.S. Caudle, T.K. Yu, and S.L. Tucker Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy Breast Cancer Res 14 2012 R83
30. M.C. Cheang, S.K. Chia, and D. Voduc Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer J Natl Cancer Inst 101 2009 736 750